Management of advanced non-small cell lung cancer: Current trends

Current Opinion in Pulmonary Medicine

Volumn 8, Issue 4, 2002, Pages 251-256

  Haura, Eric B ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; 9 AMINOCAMPTOTHECIN; BEXAROTENE; CARBOPLATIN; CISPLATIN; DOCETAXEL; FLAVOPIRIDOL; GEMCITABINE; GREEN TEA EXTRACT; IRINOTECAN; NAVELBINE; OXALIPLATIN; PACLITAXEL; PROTEIN P53; TOPOTECAN; TRASTUZUMAB; VALSPODAR;

BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; FEBRILE NEUTROPENIA; GENETIC POLYMORPHISM; HUMAN; HYPERLIPIDEMIA; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; NAUSEA AND VOMITING; PREDICTION; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0036280055     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200207000-00002     Document Type: Review

References (38)

1. Cancer statistics, 2000
2. Chemotherapy in nonsmall-cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials
3. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: Sobering results
4. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial
5. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594
6. Duration of chemotherapy in advanced non-small-cell lung cancer: A randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin
7. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: A randomised multicenter trial
8. Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable nonsmall-cell lung cancer
9. Flexible chemotherapy regimen with gemcitabine and vinorelbine for metastatic nonsmall cell lung carcinoma: A phase II multicenter trial
10. Gemcitabine plus vinorelbine in stage IIIB or IV nonsmall-cell lung cancer (NSCLC): A multicenter phase II clinical trial
11. An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with nonsmall-cell lung cancer previously treated with cisplatin-based chemotherapy: A phase II study of the Hellenic Co-operative Oncology Group
12. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens
13. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
14. Phase I/II trial of docetaxel and vinorelbine in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy
15. Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer
16. Weekly irinotecan and cisplatin in advanced nonsmall-cell lung cancer: A multicenter phase II study
17. Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer
18. A phase II trial of 9-aminocaptothecin (9-AC) as a 120-hour infusion in patients with nonsmall-cell lung cancer
19. Phase II study of S-1, a novel oral fluorouracil, in advanced non-small- cell lung cancer
20. Phase I/II study of escalating doses of vinorelbine in combination with oxaliplatin in patients with advanced non-small-cell lung cancer
21. Chemotherapy for a patient with advanced non-small-cell lung cancer during pregnancy: A case report and a review of chemotherapy treatment during pregnancy
22. Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer
23. Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: Results of a multicenter phase II study
24. Phase I trial of oral green tea extract in adult patients with solid tumors
25. A phase II trial of the cyclin-dependent kinase inhibitor Flavopiridol in patients with previously untreated stage IV nonsmall-cell lung cancer
26. Phase II study of pemeterxed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: A study of the National Cancer Institute of Canada Clinical Trials Group
27. Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833
28. Expression of her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relation to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents
29. Development of inhalational agents for oncologic use
30. Angiogenesis inhibitors in the treatment of lung cancer
31. Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III nonsmall-cell lung cancer: A Cancer and Leukemia Group B study
32. Predicting response to paclitaxel/carboplatin-based therapy in non-small cell lung cancer
33. Predictive molecular markers in nonsmall-cell lung cancer
34. UGT1a1 genotyping correlates with toxicity and survival in non-small-cell lung cancer (NSCLC) patients treated with second-line CPT-11/docetaxel
35. Altered ERCC1 expression correlates with response to cisplatin (DDP) + gemcitabine (gem) in non-small-cell lung cancer (NSCLC) patients (pts.)
36. Predicting the sites of metastases from lung cancer using molecular biologic markers
37. Correlation between c-erbB-4 receptor expression and response to gemcitabine-cisplatin chemotherapy in non-small-cell lung cancer
38. Assessment of IAP (inhibitor of apoptosis) proteins as predictors of response to chemotherapy in advanced non-small-cell lung cancer patients